← Back to Clinical Trials
Recruiting Phase 2 NCT07673380

NCT07673380 Leveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07673380
Status Recruiting
Phase Phase 2
Sponsor Washington University School of Medicine
Condition Opioid Use
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2025-08-31
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
uMAT-R + enhanced community engagementOriginal uMAT-R supplementary mHealth recovery intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 300 participants in total. It began in 2025-08-31 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The sequential trial compares recovery and mHealth engagement outcomes among Black participants who participated in the mHealth intervention uMAT-R or uMAT-R + enhanced community engagement. The mHealth intervention seeks to support people in various stages of recovery who are also seeking other forms of substance use treatment. Participants are recruited from community-based substance use treatment facilities and recovery services. Participants must be adults who have or are currently using opioids and/or stimulants.

Eligibility Criteria

Inclusion Criteria: * Have a history of opioid and/or stimulant use * Identify as Black and/or African American * Seek treatment at local substance use treatment centers * Fluent in English * U.S. resident * 18 years of age or older at the time of data collection. Exclusion Criteria: * Self-reported cognitive impairment that would limit ability to participate in research.

Contact & Investigator

Central Contact

Hannah Szlyk

✉ szlyk@wustl.edu

📞 917-836-4225

Frequently Asked Questions

Who can join the NCT07673380 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07673380 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT07673380 currently recruiting?

Yes, NCT07673380 is actively recruiting participants. Contact the research team at szlyk@wustl.edu for enrollment information.

Where is the NCT07673380 trial being conducted?

This trial is being conducted at St Louis, United States.

Who is sponsoring the NCT07673380 clinical trial?

NCT07673380 is sponsored by Washington University School of Medicine. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology